Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gemini Therapeutics Inc (NQ: GMTX ) N/A UNCHANGED Last Price Updated: 3:59 PM EST, Dec 29, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Gemini Therapeutics Inc Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation February 21, 2023 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX August 12, 2022 From Kahn Swick & Foti, LLC Via Business Wire GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders August 10, 2022 From Halper Sadeh LLP Via Business Wire Gemini Therapeutics and Disc Medicine Announce Merger Agreement August 10, 2022 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Provides Corporate Update February 28, 2022 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Provides GEM103 Program Update January 10, 2022 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update November 15, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Poster Presentation at AAO 2021 November 12, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics to Participate in Upcoming Investor Conferences November 11, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit October 19, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) October 14, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy October 05, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics September 10, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual September 09, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 07, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit August 30, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update August 12, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference August 10, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration June 22, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference May 26, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update May 13, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy May 13, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors May 03, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 01, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) April 13, 2021 From Gemini Therapeutics, Inc. Via Business Wire Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer April 12, 2021 From Gemini Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
